Clinical Trial Update: A Single-arm, Open, Exploratory Clinical Study of Allogeneic CAR-T Cells in the Treatment of Relapsed/Refractory Brain Gliomas With Positive CD70 Expression [EARLY_Phase 1]

View source ↗

Summary

This is an early-phase, single-arm trial testing allogeneic CD70-directed CAR-T cells in patients with relapsed or refractory gliomas that express CD70.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gliomas

Drugs mentioned

• CD70-directed allogeneic CAR-T cells (CD70-targeted CAR-T cells)

Snippet

Sponsor: JIANG LONGWEI | Conditions: Gliomas | EARLY_Phase 1 | Status: RECRUITING